Healthcare / Drug Manufacturers - Specialty & GenericJakarta
$384.00
-20.00 (-4.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.1T · quality 84.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.30T
P/E
9.9x
↓EV/EBITDA
6.8x
↓ROE
39.4%
↑Gross Margin
58.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.8%
FCF CAGR
+8.8%
FCF margin
29.3%
FCF / Net income
0.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.08T · net income $1.23T · FCF $1.19T
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4079.66B | $4079.66B | $3919.08B | $3565.93B | $3865.52B |
| Net Income | $1229.20B | $1229.20B | $1171.03B | $950.65B | $1104.71B |
| EBITDA | $1601.96B | $1601.96B | $1522.70B | $1229.55B | $1426.99B |
| EPS | 41.36 | 41.36 | 39.03 | 31.69 | 36.82 |
| Gross Margin | 58.0% | 58.0% | 58.7% | 56.6% | 56.1% |
| Operating Margin | 37.3% | 37.3% | 37.6% | 33.9% | 35.6% |
| Net Margin | 30.1% | 30.1% | 29.9% | 26.7% | 28.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.87 | 5.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1194.86B | $1194.86B | $1105.19B | $1005.01B | $928.73B |
| Returns | |||||
| ROE | 39.4% | 39.4% | 33.6% | 28.1% | 31.5% |
| Valuation | |||||
| P/E | 9.94 | 9.94 | 14.86 | 16.41 | 20.23 |
| EV/EBITDA | 6.84 | 6.84 | 10.87 | 12.02 | 15.02 |
| P/B | 3.66 | 3.66 | 4.99 | 4.61 | 6.38 |
| Growth & Yield | |||||
| Revenue Growth | 4.1% | 4.1% | 9.9% | -7.8% | — |
| EPS Growth | 6.0% | 6.0% | 23.2% | -13.9% | — |
| Dividend Yield | 9.6% | 9.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-6.3%
EPS terminal req.
$34.07
Spread vs growth
12.2%
5Y implied EPS CAGR
-0.1%
EPS terminal req.
$41.23
Spread vs growth
6.0%
10Y implied EPS CAGR
4.8%
EPS terminal req.
$66.40
Spread vs growth
1.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.2%
Start / end P/E
13.8x → 9.3x
EPS bridge
39.03 → 41.36
Residual
-2.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.